SLC5A2 and familial primary hypomagnesemia: Polypharmacy is recognized as a risk factor for hypomagnesemia, while the association between SGLT2 inhibitors (SGLT2i) and hypomagnesemia remains underreported.<h4>Methods</h4>To investigate this relationship, a retrospective cross-sectional study was conducted on patients aged 60 and older with Type 2 dia-betes, utilizing data from Wenzhou Central Hospital between January 2023 and December 2024.